| ID | Sequence | Length | GC content |
|---|---|---|---|
| ACGCCACCGGUGACCUCCGACGCCCCGGGCAAGAGAACGCCAGGAGGGA… | 2068 nt | 0.4328 | |
| ACGCCACCGGUGACCUCCGACGCCCCGGGCAAGAGAACGCCAGGAGGGA… | 1989 nt | 0.4354 | |
| ACGCCACCGGUGACCUCCGACGCCCCGGGCAAGAGAACGCCAGGAGGGA… | 2736 nt | 0.4616 | |
| ACGCCACCGGUGACCUCCGACGCCCCGGGCAAGAGAACGCCAGGAGGGA… | 2108 nt | 0.4369 | |
| ACGCCACCGGUGACCUCCGACGCCCCGGGCAAGAGAACGCCAGGAGGGA… | 1967 nt | 0.4326 | |
| ACGCCACCGGUGACCUCCGACGCCCCGGGCAAGAGAACGCCAGGAGGGA… | 2086 nt | 0.4343 |
Enables ethanolamine-phosphate phospho-lyase activity. Predicted to act upstream of or within several processes, including cellular response to glucocorticoid stimulus; ceramide phosphoethanolamine catabolic process; and phospholipid transfer to membrane. Predicted to be located in mitochondrial matrix. [provided by Alliance of Genome Resources, Jul 2025]
A study in humans analyzing heart tissue samples from patients with various structural heart diseases identified the ETNPPL as a differentially expressed gene within a 62-gene signature, where it was significantly down-regulated in diseased samples compared to controls with a mean fold change of 0.5824 and an adjusted p-value of 5.0566 × 10^-12 [Fajarda et al. DOI:10.1186/s13040-020-00217-8]. This signature, derived from merged microarray datasets and selected via random forest classification, achieved a mean accuracy of approximately 94.92% in distinguishing diseased from non-diseased cardiac samples. A study in mice demonstrated that the ETNPPL mRNA was significantly upregulated in ante-mortem burned skin compared to control tissue [Liu et al. DOI:10.1007/s12024-022-00474-5].